Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy
(de novo is a phrase from Latin describing some biological process that has begun again)
During a period with improvements in the treatment of advanced prostate cancer, there was a simultaneous clinically meaningful increase in mean survival for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to a study published online Oct. 2 in JAMA Network Open.
Researchers examined changes in survival with the introduction of doublet therapy (androgen deprivation therapy combined with either docetaxel or an androgen receptor pathway inhibitor) for advanced prostate cancer. The analysis included data from 11,382 men with de novo mCSPC identified in the Prostate Cancer Database Sweden (2008 to 2020).
The researchers found a shift toward less advanced prostate cancer during the study period with a decrease in median prostate-specific antigen at diagnosis in men with mCSPC. There was an increase seen in upfront treatment with doublet therapy. In addition, there was an increase noted in the adjusted five-year overall survival and an increase in mean survival during the first five years after diagnosis. “Between 2008 and 2020, mean survival increased with six months after five years of follow-up in all individuals with de novo mCSPC, taking changes in age, comorbidity, and cancer characteristics into account, supporting that doublet therapy is effective in clinical practice on a population basis,” the authors write.
JAMA Netw Open. 2023;6(10):e2336604. doi:10.1001/jamanetworkopen.2023.36604
